Cancer Gene Therapy

Introgen Receives Broad U.S. Patent for Improved Storage-Stable Formulations of its Adenoviral-Based Pharmaceuticals

Published in Vaccine Weekly, July 18th, 2007

Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that a patent covering adenovirus compositions including its product ADVEXIN has been awarded by the U.S. Patent and Trademark Office. Patent number 7,235,391, titled Formulations of Adenovirus for Gene Therapy, relates to improved pharmaceutical formulations for the long-term storage of adenoviruses.

David L. Parker, Ph.D, J.D., Introgen's senior vice president of Intellectual Property said, "The issuance of this patent is significant for Introgen in that the development of adenoviral formulations with improved storage stability and ease of shipping and handling is a is sought-after goal by the adenovirus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry